Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Free Cash Flow (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Free Cash Flow for 16 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 43.52% to $1.2 million in Q4 2025 year-over-year; TTM through Nov 2025 was $5.2 million, a 45.49% increase, with the full-year FY2025 number at $5.2 million, up 45.49% from a year prior.
  • Free Cash Flow was $1.2 million for Q4 2025 at Cryo Cell International, down from $2.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $2.7 million in Q1 2021 to a low of -$8.5 million in Q3 2022.
  • A 5-year average of $671620.2 and a median of $1.2 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 1720.11% in 2022, then soared 2891.35% in 2025.
  • Cryo Cell International's Free Cash Flow stood at $1.4 million in 2021, then soared by 76.92% to $2.5 million in 2022, then tumbled by 33.62% to $1.6 million in 2023, then surged by 31.87% to $2.1 million in 2024, then tumbled by 43.52% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Free Cash Flow are $1.2 million (Q4 2025), $2.5 million (Q3 2025), and $644606.0 (Q2 2025).